Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin. by Aarts, F. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS
Volume 23, Number 3, 2008
© Mary Ann Liebert, Inc.
DOI: 10.1089/cbr.2007.0455
Hyperthermia and Fibrinolytic Therapy 
Do Not Improve the Beneficial Effect of
Radioimmunotherapy Following Cytoreductive
Surgery in Rats with Peritoneal Carcinomatosis of
Colorectal Origin
Frits Aarts,1 Thijs Hendriks,1 Otto C. Boerman,2 Wim J.G. Oyen,2 and Robert P. Bleichrodt1
1Department of Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
2Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The
Netherlands
ABSTRACT
Background and Objective: Cytoreductive surgery (CS) and heated intraperitoneal chemotherapy
(HIPEC) are standard treatment for peritoneal carcinomatosis (PC) of colorectal cancer. Previously, we
demonstrated that preclinical radioimmunotherapy (RIT) adjuvant to surgery in PC is a good alternative
for HIPEC. Now we aimed to improve the effectiveness of RIT by combining it with whole-body hyper-
thermia (WBH) or fibrinolytic therapy. Methods: Rats were inoculated intraperitoneally with colon car-
cinoma cells. Animals underwent CS, CS  WBH (40°C, 3 hours), CS  RIT (74 MBq 177Lu-labeled MG1),
or CS  WBH  RIT. In the second experiment, rats underwent CS, CS  RIT, CS  recombinant tissue
plasminogen activator (rtPA, twice daily, 3 days), or CS  RIT  rtPA. Results: Median survival after
CS and CS  WBH was 34 and 37 days. Median survival after CS  RIT or CS  RIT  WBH was 63
and 86 days (p  0.0003, p  0.0006 compared to CS  WBH). Median survival after CS and CS  rtPA
was 50 and 42 days (p  0.1). Median survival was 106 days after CS  RIT and 103 days after CS 
RIT  rtPA (p  0.0001 compared to CS  rtPA). No difference was found between CS  RIT and CS 
RIT  rtPA (p  0.83). Conclusions: The application of WBH or rtPA in combination with adjuvant RIT
after CS for the treatment of PC of colonic was feasible but did not significantly potentiate the efficacy of
RIT.
Key words: peritoneal carcinomatosis, cytoreductive surgery, radioimmunotherapy, hyperthermia, fibri-
nolytic therapy, targeted radionuclide therapy
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INTRODUCTION
Cytoreductive surgery (CS) followed by hyper-
thermic intraperitoneal chemotherapy (HIPEC) is
considered one of the most promising treatments
of peritoneal carcinomatosis (PC) of colorectal car-
cinoma (CRC).1 In HIPEC, hyperthermia is used
to enhance the chemosensitivity of the tumor.2 Me-
dian survival after these radical surgical debulking
procedures (cytoreduction) is 13–34 months with
a 5-year survival of 19%–27%, which constitutes
a significant improvement to palliative treatment
consisting of chemotherapy and palliative sur-
gery.3–7 However, the improved survival is reached
at the cost of a considerable morbidity of 23% and
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a mortality of 4%.4,8 Thus, the search for alterna-
tive treatment strategies is warranted.
Radioimmunotherapy (RIT) using radiolabeled
monoclonal antibodies directed against tumor-as-
sociated antigens may be an attractive anticancer
therapy in patients with small-volume disease.9 In
previous studies we have demonstrated the efficacy
of RIT as an adjuvant to surgery in an animal model
of PC. Survival in Wag/Rij rats with intraperitoneal
CC-531 (colon carcinoma) tumors was signifi-
cantly improved if CS was followed by adjuvant
RIT using the 177lutetium-labeled anti-CC531
monoclonal antibody (MAb) MG1.10 The effect
was most explicit when RIT treatment was admin-
istered immediately following surgery, as com-
pared to 4 or 14 days after surgery.11 In rats with
intraperitoneal CC531 tumors, RIT was found to
be at least as effective as HIPEC in terms of sur-
vival after CS, and RIT induced fewer side effects
than the adjuvant treatment with HIPEC.12 These
experiments suggest that RIT is a promising ther-
apeutic approach to ameliorate treatment of PC.
The question now arises whether the efficacy of
adjuvant RIT can be further improved.
It has been shown in preclinical studies with sub-
cutaneously growing xenografts that the efficacy of
RIT can be enhanced by locally applied hyper-
thermia.13 Hyperthermia increases tumor blood
flow and interstitial pO2, reducing tumor hypoxia
and disturbed cellular repair mechanisms.14–16
During surgical procedures, tissue damage
causes deposition of fibrin, which may result in the
formation of fibrinous adhesions. This phenome-
non occurs as the result of a shift in the equilibrium
between coagulation and fibrinolysis, in favor of
the coagulation system.17–19 Tumor cells may be
trapped in these fibrin clots and become inaccessi-
ble to therapeutic agents, such as radiolabeled an-
tibodies, which may promote tumor growth.20–22
Postoperative fibrinolytic therapy might prevent
these events from occurring. Here, we report on 2
separate animal studies where we investigated if ei-
ther whole-body hyperthermia or fibrinolytic ther-
apy (with tissue-type plasminogen activator [rtPA])
could improve the efficacy of adjuvant RIT, as ap-
plied after CS for PC of colonic origin.
MATERIALS AND METHODS
Experimental Design
Two (2) experiments were performed to study
the effects of hyperthermia and rtPA, respec-
tively. In both experiments, intraperitoneal tu-
mor growth was induced by the inoculation of
tumor cells. After 7 days, CS was performed.
In the hyperthermia experiment, 60 rats, 15 in
each treatment group, were randomly assigned
to undergo either CS alone, CS followed by
whole-body hyperthermia (CS  H), CS fol-
lowed by RIT (CS  RIT), or CS followed by
whole-body hyperthermia and RIT (CS 
HRIT). In the fibrinolysis experiment, 58 rats
were randomly assigned to undergo CS alone
(CS, n  15), CS followed by rtPA treatment
(CS  rtPA, n  15), CS followed by RIT
(CS  RIT, n  13), or a combination of both
adjuvant treatments (CS  RIT  rtPA, n 
15). In both experiments, survival was deter-
mined and at autopsy the extent of tumor
growth was scored.
Cell Line
The syngeneic rat colon carcinoma cell line
CC531, originally induced in Wag/Rij rats by in-
travenous injection of 1,2-dimethylhydrazine,23
was cultured and maintained as monolayer in
RPMI-1640 medium (Invitrogen, Breda, The
Netherlands) supplemented with 10% fetal calf
serum (GIBCO), 2 mM L-glutamine, penicillin
(100 U/mL), and streptomycin (100 g/mL) at
37°C in a humidified atmosphere with 5% CO2.
Before inoculation, tumor cells were washed with
0.9% sodium chloride, disaggregated with 0.25%
trypsin, and resuspended in 0.9% phosphate-
buffered saline (PBS) to a concentration of 1 
106 cells/mL; 2 mL of this cell suspension was
injected intraperitoneally, as previously de-
scribed.10
Animals
Male Wag/Rij rats, 10 to 12 weeks old (body
weight 240–285 g, Harlan, Horst, The Nether-
lands) were accustomed to laboratory conditions
for at least 1 week before experimental use and
housed under nonsterile standard conditions
(temperature, 20°C–24°C; relative humidity,
50%–60%; 12-hour light/dark cycle) in filter-
topped cages (2 rats per cage), with free access
to food (Ssniff, Bio Services, Uden, The Nether-
lands) and water. Physical condition was exam-
ined daily and body weight was recorded daily
during the first 14 days after surgery by a biotech-
nician, who was blinded to the therapeutic regi-
men. Thereafter, body weight was recorded
weekly. All experiments were approved by the
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local Animal Welfare Committee of the Radboud
University Nijmegen and were carried out in ac-
cordance with the Dutch Animal Welfare Act of
1997.
Cytoreductive Surgery
Surgical procedures were performed under gen-
eral anesthesia using isoflurane 3%, O2 and N2O
1:1. All rats underwent a midline laparotomy, fol-
lowed by careful inspection of the abdominal
contents for the presence of tumor. Tumor growth
at each of the intra-abdominal quadrants was then
scored as 0 (no macroscopic tumor growth), 1
(limited), 2 (moderate), or 3 (abundant). The peri-
toneal cancer index (PCI) was then the sum of
the score for the four quadrants as described pre-
viously.10
In all treatment groups, CS was performed, in-
cluding a routine omentectomy, and all macro-
scopic tumor deposits were removed surgically.
Unresectable tumors were cauterized. After com-
pletion of the surgical cytoreduction, the abdom-
inal wall was closed in 2 layers using continuous
Vicryl 3-0 sutures for the muscular component
and iron wound clips for the wound. After com-
pletion of the procedure, 10 mL of warmed, nor-
mal NaCl solution, 0.9% was given subcuta-
neously for rehydration. Thirty (30) minutes prior
to surgery and once daily until the third postop-
erative day, rats were given buprenorphine (5 g,
0.1 mL/rat/d) subcutaneously for analgesia.
Radioimmunotherapy
The murine MG1 MAb, an anti-CC531 IgG2a
monoclonal antibody (Antibodies for Research
Applications BV, Gouda, The Netherlands) that
recognizes an 80-kDa cell surface antigen on
CC531 cells, was used in these studies. The MG1
MAb localizes preferentially in tumors when in-
jected in rats bearing CC-531 tumors.24 Labeling
of the antibody with 177Lu (half-life 7 days, -
energy 149 keV, - energy 208 keV, penetration
depth 3 mm) was carried out as previously de-
scribed.10 In brief, the MAb was conjugated with
2-(4-isothiocyanatobenzyl)-diethylenetriamine-
pentaacetic acid (Macrocyclics, Dallas, TX), sub-
sequently labeled with 177lutetium (IDB Holland,
Baarle Nassau, The Netherlands), and purified by
gel filtration on a PD10 column (Amersham,
Pharmacia Biotech, Maarsen, The Netherlands).
The purified 177Lu-MG1 preparation was diluted
in PBS with 0.5% bovine serum albumin for in-
jection. The specific activity of the administered
177Lu-MG1 preparation was 0.4 MBq/g. The
177Lu labeling procedure was performed under
strict metal-free conditions.
177Lu-labeled MG1 was used as the therapeutic
agents in these experiments based on the favor-
able tumor-to-blood ratios obtained with 111In-la-
beled MG1 in this model as compared to 125I-la-
beled MG1 (9.2  5.3 vs. 2.4  1.4 with p 
0.040) reported by Koppe et al.10 In addition, it
was shown that intraperitoneal RIT using177Lu-
labeled antibodies to treat small peritoneal metas-
tases resulted in the highest percentage survival
as compared to treatment with 131I-, 186Re-, or
90Y-labeled antibodies.25
RIT (185 g MG1/rat, radiolabeled with 74
MBq 177Lu in 3.0 mL) was intraperitoneally in-
jected immediately following surgery, as this was
determined to be the most optimal time for adju-
vant administration in relation to CS.11 In addi-
tion, this was presumed to be the most optimal
time in relation to the application of hyperther-
mia.26
Hyperthermia
Immediately upon recovery from general anes-
thesia, animals in the CS  H group and the
CS  HRIT group were placed in an incubator
preset at a temperature of 39°C. After 30 min-
utes, the temperature was raised to 40°C. Inside
the incubator, conditions were similar to those
within the animal facility housing: a relative hu-
midity between 20% and 40%. General whole-
body hyperthermia was maintained for 3 hours.
The rectal temperature was monitored every 30
minutes.
Fibrinolytic Therapy
Immediately after the surgical procedure and af-
ter closure of the abdominal wall, the fibrinolytic
therapy was administrated. Fibrinolytic therapy
comprised of the intraperitoneal administration of
1.25 mg human rtPA (Actilyse, Boehringer, In-
gelheim, Germany) twice daily during the first 3
days after surgery. This dose was chosen because
it was shown to be effective in reducing in-
traperitoneal abscess formation in a model of in-
duced peritonitis in rats.27
Follow-Up
The primary endpoint in both experiments was
survival. Animals were observed daily by an ex-
perienced biotechnician, blinded to the therapeu-
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tic regimen, who determined the humane end-
point. When this was reached (signs of massive
hemorrhagic ascites, physical inactivity, or signs
of intra-abdominal tumor growth with invalidat-
ing consequences), rats were killed by O2/CO2
asphyxiation and immediately dissected. At dis-
section, the intraperitoneal tumor growth was
scored as described above. At 16 weeks postop-
eratively, the study was terminated and the re-
maining rats were killed and dissected. In case of
absence of macroscopic tumor, all relevant or-
gans, including the greater momentum, mesen-
tery, and diaphragm, were removed for histology
in order to examine tumor presence microscopi-
cally. Tissues were fixed in 1% formaldehyde,
dehydrated, and embedded in paraffin. Sections
were stained using hematoxylin and eosin and
immunohistochemically stained using the murine
MG1 antibody in combination with a peroxidase-
conjugated horse-anti-mouse IgG antibody (Vec-
tor Laboratories Inc., Burlingame, CA, USA).
Statistical Analysis
Statistical analysis was performed using SPSS
(Chicago, IL) software and Graphpad Prism ver-
sion 4.0 (Graphpad Software Inc., San Diego,
CA) for analysis. Comparison of dichotomous
values was done using chi-square or Fisher exact
test. Nonparametric testing was performed using
2-way analysis of variance testing. Survival
curves were analyzed using Kaplan-Meier curves
and compared by means of the log-rank test. Post-
testing using Bonferroni was applied to correct
for multiple groups. All tests were 2-sided; the




Surgery and adjuvant treatment
Preoperative clinical condition and body weight did
not differ between groups. At laparotomy, tumor
nodules were often present in the omentum, liver
hilum, mesentery, and gonadal fat pads (1–3 mm
diameter). Median PCI score at time of surgery was
8 (range 0–12, Table 1) and did not differ between
groups (p  0.59). After CS, 2 of the 15 animals
in the CS group had residual disease after surgery.
During surgery, a bowel perforation occurred in 1
rat. No animals died during or immediately after
surgery. Mean rectal temperatures during hyper-
thermia were equal in both hyperthermia groups:
39.4°C  0.8°C in the CS  H group and 39.5° 
1.2°C in the CS  HRIT group, respectively. Two
(2) animals were euthanized directly after hyper-
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Table 1. Treatment Group Characteristics
Disease
characteristics CS CS  H CS  RT CS  HRIT CS CS  rtPA CS  RIT CS  RIT  rtPA
Body weight 264 265 265 268 274 274 275 274
preoperative (246–281) (251–278) (249–282) (252–285) (257–290) (260–288) (253–292) (263–287)
Tumor score per site
Greater omentum 2 (1–3) 2 (0–3) 2 (1–3) 2 (2–3) 1 (1)–1 1 (1–3) 1 (1)–1 1 (1)–1
Liver hilum 2 (1–3) 2 (0–2) 2 (0–3) 2 (1–2) 1 (0–2) 1 (1)–1 1 (0–1) 1 (1–2)
Perisplenic 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–1) 1 (0–1) 1 (1–0) 0 (0–1) 1 (0–1)
Mesentery 1 (0–2) 1 (0–2) 1 (0–2) 2 (1–3) 1 (0–1) 1 (0–3) 1 (0–1) 1 (0–1)
Gonadal fat pads 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–1) 0 (0–1) 1 (0–1) 0 (0–1)
Diaphragm 0 (0–1) 0 (0–1) 0 (0)–1 0(0)–1 0 (0)–1 0 (0)–1 0 (0)–1 0 (0)–1
Parietal peritoneum 1 (0–2) 1 (0–2) 1 (0–2) 1 (1–2) 1 (0–1) 0 (0–1) 1 (0–1) 0 (0–3)




Yes 13 15 15 15 15 15 13 15
No 2 0 0 0 0 0 0 0
CS, cytoreductive surgery; H, whole-body hypothermia; RIT, radioimmunotherapy; HRIT, whole-body hypothermia and 
radioimmunotherapy; rtPA, tissue-type plasminogen activator. 
Results are median (range).
Hyperthermia Fibrinolytic therapy
thermia, 1 in the CS  H group and 1 in the CS 
HRIT group. Two (2) animals showed massive un-
explained weight loss (1 each in the CS and CS 
HRIT groups) and were euthanized 4 days after sur-
gery. All animals lost weight after surgery (Fig.
1A). Maximum weight loss was 7.6%  1.3%
(mean and standard deviation) and 8.5%  0.8%
for the CS and CS  H groups and 10.3%  0.4%
and 10.7%  0.7% for the CS  RIT and CS 
HRIT groups, respectively. At day 4 and day 5 af-
ter surgery, weight loss was significantly higher in
the CS  RIT group than in the CS group (p 
0.05). In addition, from day 5 until day 9, animals
that were treated with CS  HRIT lost signifi-
cantly more body weight as compared to animals
treated with CS alone (p  0.05).
Follow-up
Forty-nine (49) out of 56 animals reached the hu-
mane endpoint within 16 weeks after surgery. At
time of death, mean PCI in the CS, CS  H, CS 
RIT, and CS  HRIT groups was 20 (range
16–21), 20 (range 14–21), 17 (range 12–20), and
15 (range 2–21), respectively (Fig. 2A). The PCI
was significantly lower in the CS  HRIT group
than in both the CS (p  0.01) and CS  H (p 
0.05) groups. All these animals showed hemor-
rhagic ascites. At dissection, the volume of ascites
was equal in all 4 groups (mean 19.9 g, p  0.35).
Median survival after CS was 34 days (range
25–112, end of study) and after CS  H, 37 days
(range 15–83, Fig. 3A). The groups that were
treated with adjuvant RIT survived significantly
longer; after CS  RIT, median survival was 63
days (range 39–112, p  0.0003 vs. CS  H) 
and after CS  HRIT 86 days (range 35–112, 
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Figure 1. Course of body weight during the first 2 weeks
after cytoreductive surgery. Body weight (mean  standard
deviation) is given relative to weight at operation. (A) Ef-
fect of hyperthermia; (B) effect of tissue-type plasminogen
activator (rtPA). , CS; , CS  H; , CS  RIT; , CS 
HRIT; , CS; ✖, CS  rtPA; , CS  RIT; , CS 
RIT  rtPA. See text for description of groups.
Figure 2. Peritoneal cancer index (PCI) at time of death.
Individual values are given together with the median (hori-
zontal bar). In the hyperthermia experiment (A), the PCI was
significantly lower in the CS  HRIT group than in both the
CS (p  0.01) and CS  H (p  0.05) groups. In the rtPA
experiment (B), the PCI was significantly lower in the CS 
RIT group than in both the CS (p  0.01) and CS  RIT 
rtPA (p  0.05 and p  0.01, respectively) groups. , CS;
, CS  H; , CS  RIT; , CS  HRIT; , CS; ✖, CS 






p  0.0006 vs. CS  H). However, the apparent
difference between the latter groups remained non-
significant (p  0.72).
Seven (7) rats (1 in the CS group, 4 in the CS 
RIT group, and 2 in the CS  HRIT group) sur-
vived until 16 weeks after surgery and were killed
subsequently. Three (3) of these animals had
macroscopic tumor (2 in the CS  RIT group and
1 in the CS  HRIT group). Microscopic investi-
gation of the remaining 4 animals did not reveal
any tumor.
Fibrinolytic Therapy
Surgery and adjuvant treatment
Preoperative clinical condition and body weight
did not differ between groups. At laparotomy, tu-
mor nodules were present in the omentum, liver
hilum, mesentery, and gonadal fat pads (1–3 mm
diameter). The median PCI score at time of sur-
gery was 5 (range 3–10) and was similar in all
groups (p  0.28, Table 1). No animals died dur-
ing or immediately after surgery. One (1) animal
in the CS  RIT group was killed 2 days after sur-
gery due to a burst abdomen. All animals lost
weight after surgery (Fig. 1B). Maximum weight
loss was 6.6%  2.6% and 7.9%  3.8% in the
CS and CS  rtPA groups and 10.1%  2.6% and
9.5%  5.8% in the CS  RIT and CS  RIT 
rtPA groups, respectively. There was a significant
difference in weight loss between the CS and
CS  rtPA groups from day 2 until day 4 (p 
0.05). In addition, from day 3 up until day 13, an-
imals treated with RIT or RIT  rtPA lost signif-
icantly more weight than animals treated with CS
alone (p  0.01 and p  0.05, respectively).
Follow-up
Forty-seven (47) out of 57 animals reached the
humane endpoint before the termination of the ex-
periment 16 weeks after surgery. The mean PCI
at the time of death in the CS, CS  rtPA, CS 
RIT, and CS  RIT  rtPA groups was 17 (range
14–21), 20 (range 13–21), 15 (range 0–19), and
17 (range 7–21), respectively (Fig. 2B). The PCI
was significantly lower in the CS  RIT group
than in both the CS alone (p  0.01) and CS 
RIT  rtPA (p  0.05 and p  0.01, respec-
tively) groups. No difference in the volume of as-
cites was found between the groups at the time of
sacrifice. Median survival after CS alone and
CS  rtPA was 50 days (range 30–112) and 42
days (range 23–67) (p  0.09), respectively. The
groups that were treated with adjuvant RIT sur-
vived significantly longer (Fig. 3B). The median
survival of animals that were treated with CS 
RIT was 106 days (range 54–112), and those
treated with CS  RIT  rtPA survived for 103
days (range 46–112; p  0.0001 when compared
to CS  rtPA for both these treatment groups).
There was, however, no difference in survival be-
tween both RIT-treated groups (p  0.52).
Of the 10 animals that were still alive at the
end of the experiment (1 in the CS group, 5 in
the CS  RIT group, and 4 in the CS  RIT 
rtPA group), 3 animals (2 in the CS  RIT group
and 1 in the CS  RIT  rtPA group) showed
macroscopic and 1 (in the CS  RIT group)
showed microscopic tumor at dissection.
DISCUSSION
The present data demonstrate that application of
RIT immediately after surgery more than doubles
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Figure 3. Survival in days. In the hyperthermia experi-
ment (A), the groups that were treated with adjuvant RIT
survived significantly longer than those in the fibrinolysis
experiment (B). , CS; , CS  H; , CS  RIT; , CS 
HRIT; , CS; ✖, CS  rtPA; , CS  RIT; , CS 
RIT  rtPA. See text for description of groups.
A
B
survival time. However, the results of both ex-
periments demonstrate that the efficacy of RIT as
an adjuvant treatment after CS for PC is not sig-
nificantly improved by hyperthermic treatment or
the use of fibrinolytic drugs in an established
model of PC in the rat.
In Wag/Rij rats, the intraperitoneally growing
syngeneic rat colon carcinoma cell line CC531
has been shown to present a highly reproducible
model of PC that is similar to the human entity
of PC.28 We have shown before that RIT with
177Lu-labeled MG1, administered after CS, is a
promising adjuvant treatment.10,11
In the clinical situation, hyperthermia may en-
hance the effect of radiotherapy during 1 hour
and combined with a single high dose of radio-
therapy.29 The application of prolonged (3–6
hours) mild whole-body hyperthermia (40°C) in
combination with low-dose RIT (131I-labeled
anti-carcinoembryonic antigen (CEA) antibody
F-33-104) delayed the growth of subcutaneously
growing human colon cancer xenografts.30 The
6-hour course of hyperthermia led to a mortality
of 23%. Probably, a shorter time of hyperthermia
is effective as well. It has been shown that the ef-
fects of hyperthermia (i.e., increased blood flow
and oxygenation), even when applied for 60 min-
utes only, lasted for 24 hours.31 Kinuya et al.32
demonstrated an increased (2.4-fold) accumula-
tion of the radiolabeled antibody in subcuta-
neously growing human colon cancer xenografts
in nude mice, resulting in improved therapeutic
efficacy when hyperthermia was applied directly
after antibody injection. If hyperthermia was ap-
plied either 2 days prior to or 2 days after the in-
jection of the radiolabeled MAb, the opposite ef-
fect was observed. In the present study, we
therefore applied whole-body hyperthermia of
40°C immediately after the intraperitoneal injec-
tion of the radiolabeled antibody. This procedure
resulted in a hyperthermia-related mortality of
7%. In contrast to the above-mentioned studies,
the present study failed to show a significantly
enhanced therapeutic efficacy of RIT after hy-
perthermia, although the median survival in-
creased by 36%. The lack of a significant effect
of the adjuvant application of mild hyperthermia
in our model may be due to various reasons. The
microenvironmental factors influenced by hyper-
thermia are (1) perfusion, (2) vascular perme-
ability, (3) pO2, (4) pH, and (5) interstitial fluid
pressure in the tumor.31
An increase in tumor perfusion reduces hypoxia,
which may enhance radiosensitivity. This has been
reported by Mittal and colleagues,33 who used an
131I-labeled anti-CEA antibody in combination
with temperatures between 41°C and 43°C for the
duration of 45 minutes to treat human colon can-
cer xenografts. The authors concluded that hyper-
thermia increased the effectiveness of RIT but
without an increase uptake of the antibody in the
tumor. Most likely, intraperitoneally growing small
tumor nodules (1 mm) originating from CC531
cells only have a small hypoxic fraction. This may
explain the lack of increased efficacy in our model.
Increased vascular permeability is reported to
occur at temperatures exceeding 41.5°C. Under
the present experimental conditions, these high
temperatures would lead to an unacceptably high
morbidity and thus is not applicable in this model.
Abdominal surgery inevitably results in peri-
toneal trauma followed by the deposition of fi-
brin.34 Tumor cells can be encapsulated within
this fibrin network and as such would become
less accessible to intraperitoneal RIT.35 Admin-
istration of rtPA will lyse fibrin and may coun-
teract this effect. In the present study, the ad-
ministration of rtPA did not result in increased
survival. This may be due to ineffective fibrinol-
ysis. However, using a similar dose, Buyne et al.
reported that 2 intraperitoneal injections with
1.25 mg rtPA reduced abscess formation with
30% in an intra-abdominal sepsis model.27
Jacquet and colleagues found that intraoperative
administration of rtPA (5 mg/kg) resulted in a de-
creased number of tumor implants when colon
carcinoma cells were administered intraperi-
toneally after creating peritoneal wounds.36 The
applied dose of 1.25 mg twice daily for 3 days,
however, did not result in an improved survival
in the present study. Apparently, in the presently
used model, fibrin deposition is not a factor lim-
iting the effectiveness of RIT. The use of an al-
pha-emitter in this model may have been more
appropriate than the use of Lu-177. One might
argue that the penetration range of the alpha par-
ticles (70 m) is more suited for treating tumor
cell clusters and very small tumor nodules than
the penetration range of the beta particles emit-
ted by Lu-177 (3.3 mm).37
In summary, we showed that the administra-
tion of RIT adjuvant to CS in a model of induced
PC of colonic origin improves survival. In addi-
tion, we demonstrated that the application of mild
WBH or rtPA as adjunct to RIT and CS is feasi-
ble but did not show a significant additive effect
to the combined treatment of RIT and CS in our
model of PC of CRC.
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CONCLUSIONS
This study showed that the application of com-
bined WBH and RIT adjuvant to CS is feasible
but did not significantly improve the efficacy of
the combined treatment of RIT and CS in a model
of PC of CRC. The combination of both treat-
ment modalities, however, could be an effective
adjuvant treatment for PC of CRC in cases of hy-
poxic tumors. In addition, the use of fibrinolytic
therapy in the model of induced PC may be fur-
ther explored using alpha-emitters as radionu-
clides.
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